DR-531 Validation of a copy-number alteration-based genomic signature for malignant tumour progression and EGFR-targeted therapy response using the Hartwig cancer cohort

Cancer genomes often show large-scale copy-number alterations that may reflect tumour aggressiveness, genomic instability and resistance to therapy. We have developed a copy-number alteration-based genomic signature, provisionally termed PUMCHS, that appears to identify tumours with malignant progression and potential relevance to targeted therapy response, particularly EGFR/MAPK-related treatment contexts.

In this project, we aim to use the Hartwig cancer dataset to externally evaluate whether this genomic signature is associated with clinical characteristics, metastatic disease patterns, treatment exposure and patient outcome. The analysis will be performed within the approved single-center data access environment by the applicant’s institution. External collaborators will not receive direct access to individual-level Hartwig data; they will only contribute to study design and interpretation of aggregated analysis results.

Gerton Lunter, UMCG, The Netherlands